|
The Board of Henderson Morley plc
(“Henderson Morley” or “the Company”), the AIM listed drug
discovery company, is pleased to provide the market and
their shareholders with an update detailing the current
status of the Company’s activities and its scientific
pipeline.
HIGHLIGHTS
• Discussions with a pharmaceutical partner regarding Koi
Herpes vaccine at an advanced stage;
• Internationally renowned consultant retained to assist
the development of PREPS and L-particles;
• It is envisaged that a final injectable formulation of
ICVT will be ready for Pre-IND discussions with the FDA by
December 2007;
• A specialist animal health Contract Research
Organisation contracted to undertake field studies to
examine the use of ICVT topical drops in the treatment of
Feline Herpes Virus (FHV) conjunctivitis;
• The first phase of the Henderson Morley’s laboratory
expansion is now complete - resulting in a newly formed
Molecular Virology Lab, enhanced virus growth capabilities
Executive Chairman Andrew Knight said: “We are continuing
to see strong interest across the portfolio as it
develops. We look forward to further updating the market
in due course.” |
